In 16 patients undergoing angioplasty of the left anterior descending coronary artery, the clinical, electrocardiographic, and hemodynamic effects of short-term intravenous nonselective ,Badrenergic blockade with propranolol (0.1 mg/kg) were assessed during temporary occlusion of the artery. Myocardial ischemia during coronary occlusion was prevented, delayed in onset, or diminished in magnitude by propranolol in 10 of the 16 patients. Propranolol decreased values for indexes of myocardial oxygen demand, such as heart rate and blood pressure and their product, in all patients.
EVALUATIONS of medications thought to be useful in patients with ischemic heart disease have usually included analysis of clinical and electrocardiographic (ECG) responses at rest or during several types of stress. Cardiac stress induced by atrial pacing, dynamic and handgrip exercise, mental arithmetic, and coldpressor tests have been studied previously because they mimic clinical situations known to cause transient myocardial ischemia in some patients. Detailed hemodynamic studies performed in patients undergoing investigative cardiac catheterization have been used to better assess mechanisms by which these stresses induce transient myocardial ischemia and mechanisms of drug action during rest and stress. In recent years the role of intermittent and permanent coronary occlusion has been recognized as a frequent cause of myocardial ischemia in patients with unstable angina and acute myocardial infarction.'-3 Evaluation of hemodynamic responses and mechanisms of drug effect during abrupt coronary occlusion in patients has been difficult because of the unavailability of a suitable human preparation. We believe that balloon occlusion during coronary angioplasty represents one preparation that can assist the assessment of clinical effects and mechanisms of drug action during acute coronary occlusion.
We have demonstrated the feasibility of the use of balloon coronary occlusion during angioplasty of the left anterior descending coronary artery to estimate pressure and flow determinants of coronary collateral function in conscious, unsedated patients and to assess responses to intravenous nitroglycerin. 4 5 The principal purpose of this study was to use this balloon-occlusion preparation to determine if the acute nonselective ,3-adrenergic blockade induced by intravenously administered propranolol diminishes myocardial ischemia during brief periods of acute occlusion of the left anterior descending coronary artery. Assuming some effect of propranolol was observed, we hoped to relate clinical and ECG responses after propranolol to hemo-dynamic findings in baseline angiographic and control and propranolol periods.
Methods
Patient population. We studied 16 patients who were 33 to 69 years of age (table I) . Each had severe stenosis (average 78 + 16%, range 5 1% to 99% diameter reduction) of the proximal left anterior descending coronary artery and was undergoing clinically indicated angioplasty of that artery. In every patient left ventricular wall motion was preserved (ejection fraction >45%) and anterior wall motion was normal or only mildly hypokinetic. In all but five patients, all vasoactive medications (j3-adrenergic blockers, calcium antagonists, and long-acting nitrates) were discontinued at least five half-lives before study. Use of sublingual nitroglycerin was permitted until 6 hr before study. In five patients (Nos. 1, 3, 5, 6, and 12) administration of calcium antagonists was continued uninterrupted before the procedure. All patients received 325 mg of aspirin orally the night before the study and 10,000 units of heparin intra-arterially at the beginning of the procedure. No intravenous or intracoronary nitroglycerin was administered until after the research portion of the experiment was completed. All patients gave written informed consent. The study was approved by the appropriate institutional review committees.
Angioplasty. Angioplasty of the left anterior descending coronary artery was performed in the usual fashion, except that calcium antagonists and nitrates were omitted (as noted). Briefly, a No. 8F angioplasty sheath (USCI) was placed percutaneously in the right femoral artery, and through it a No. 8F FL4 or FL4G guide catheter was positioned in the ascending aorta. An appropriately sized "steerable" balloon dilation catheter (USCI, 2.5 to 3.5 mm diameter, 25 mm length) was positioned through the guide catheter across the stenosis of the left anterior descending artery so that when inflated ( 1 to 2 atm) the balloon also obstructed any branches proximal to the stenosis. This was confirmed angiographically. From the right femoral vein a catheter was positioned in the pulmonary arterial wedge position to measure left ventricular filling pressure. From the right or left antecubital vein, a multithermistor catheter was positioned in the coronary sinus to measure regional coronary venous flow (thermodilution). The distal thermistor was positioned in the great cardiac vein close to its juncture with the anterior interventricular vein.
The balloon dilation catheter usually initially obstructed the left anterior descending artery an amount sufficient to lead to signs or symptoms of myocardial ischemia. In all cases several brief balloon inflations were performed to decrease the magnitude of obstruction. The balloon was then deflated, and pressures, the electrocardiogram, and clinical signs were monitored. None of the patients had clinical, ECG, or hemodynamic evidence of myocardial ischemia for at least 5 min before control period measurements were made.
Control period. When all evidence of transient myocardial ischemia was absent for at least 5 min, control period recordings of aortic, distal coronary, and left ventricular filling pressures; ECG leads I, II, and V5; and great cardiac vein and indicator temperature signals were made. On stabilization of these values (--+ 5%) the balloon was inflated, totally occluding the left anterior descending artery, and preventing antegrade flow to the anterior left ventricular region. Balloon inflation was continued until angina or important ECG changes occurred or for a maximum of 1 min if no signs or symptoms of ischemia occurred. At least two control recordings, separated by an ischemia-free interval of at least 5 min, were obtained from each patient.
Propranolol period. Propranolol was administered intrave- nously (0.1 mg/kg) over a 4 to 6 min interval. Ten minutes after the infusion was completed, recordings made during the control period were repeated. Definitions and calculations. Clinical evidence of myocardial ischemia was defined as the presence of chest pain typical of the patient's usual exertionally provoked symptom. Patients were also asked to grade the severity of chest pain as mild or severe. Important ECG evidence of myocardial ischemia was defined as new ST segment depression or elevation of 1 mm or more 0.08 sec after the QRS, T wave inversion, normalization of previously inverted T waves, or new peaking of the T wave. The clinical indicators of a decrease in magnitude of ischemia considered important were a change from the presence to the absence of chest pain or a decrease in severity of chest pain. ECG indicators of a decrease in magnitude of ischemia included reduction of a least 1 mm in magnitude of ST shift, ST elevation changing to only ST depression, absence of normalization of inverted T waves, and absence of T wave peaking or inversion. A delay of at least 15 sec after propranolol in onset of clinical and ECG indicators of myocardial ischemia of a magnitude similar to the last control values was also considered important.
Great cardiac vein blood flow was calculated as described elsewhere.4' 5 An index of coronary collateral resistance was calculated as the ratio of the difference between mean aortic and distal coronary pressures and great cardiac vein blood flow. Statistics. Comparisons of values before and after propranolol were made with the use of t tests for paired and unpaired samples. Additionally, the magnitude of change from the contol to the propranolol period was compared by both the t test and the Wilcoxon rank-sum test. A p value < .05 was considered indicative of statistical significance.
Results
Collection of data during the control occlusion of the left anterior descending artery was repeated at least once in all patients, twice in seven patients, and three times in one patient. These repeated occlusions before propranolol showed that clinical evidence of transient myocardial ischemia and hemodynamic data were reproducible in each patient (table 2). The difference in the time interval between occurrence of angina or ECG changes or both during the control occlusions averaged less than 5 sec and was never greater than 10 sec. Hemodynamic values during the repeated control occlusions were similar (±+ 5%), and data reported were obtained during the last occlusion before administration of propranolol. The consistency of responses during three or four control occlusions of the left anterior descending artery in eight of the patients demonstrated that tolerance was not developing.
Myocardial ischemia was never more severe during the propranolol period than during the control occlusion (table 2) . After propranolol, myocardial ischemia recurred in six patients (Nos. 11 to 16), and the time to onset and magnitude of both angina and ECG changes were similar to those during the control period. In five patients (Nos. 1 to 5) myocardial ischemia did not recur during the propranolol period, and in five other patients (Nos. 6 to 10) it was diminished in magnitude and delayed in onset. A comparison of the 10 patients (Nos. 1 to 10) who clinically benefited from propranolol with the six who did not (Nos. 1 1 to 16) showed no difference in global left ventricular ejection fraction, regional wall motion, percent reduction in diameter of the left anterior descending artery, disease in adjacent Among patients in whom propranolol reduced myocardial ischemia (0), great cardiac vein blood flow was not changed in one patient, was increased in six, and decreased in three. In contrast, in patients in whom propranolol did not change myocardial ischemia (0), great cardiac vein flow consistently decreased. in patients with less myocardial ischemia but not in patients with no change in myocardial ischemia. No complications occurred as a result of this study, and all patients underwent a clinically successful angioplasty procedure with residual stenosis of the left anterior descending artery of less than 50%.
Discussion
In approximately two-thirds of our patients, nonselective ,3-adrenergic blockade with propranolol resulted in delayed onset, diminished magnitude, or prevention of myocardial ischemia during balloon occlusion of the proximal anterior descending coronary artery. These data suggest that fl-blockade given before or possibly soon after acute coronary occlusion would be beneficial in a clinical setting. The clinical benefit of propranolol seen in some patients was expected, but the coronary hemodynamic effects were surprising. A comparison of the 10 patients who showed reduced myocardial ischemia with the six who did not have reduced ischemia after receiving propranolol showed similar heart rate, pressure, coronary flow, and resistance values before propranolol, but several differences with respect to propranolol-induced changes.
Propranolol decreased heart rate, a primary determinant of myocardial oxygen demand in all patients. Thus, the anticipated and appropriate response of great cardiac vein flow would be a reduction. That flow did not decline in a subgroup of patients (those with reduced ischemia) suggests an additional action of propranolol in reducing coronary collateral vascular resistance. It it likely that fl-blockade-induced reduction in myocardial ischemia during transient acute coronary occlusion is one mechanism leading to clinical benefit from fl-blockers in many patients with ischemic heart disease. Another consideration is that propranolol could have a direct beneficial effect on the potentially ischemic myocardium. This could not be evaluated in this protocol, but could better be studied by direct coronary injection into the affected left ventricular region. 6 In addition, we studied responses after only one fixed dose of intravenous propranolol designed to produce fl-blockade in most patients. Even more patients may have benefited if multiple incremental doses had been evaluated.
Review of the effects of propranolol on regional blood flow in experimental coronary occlusion shows that variable responses have been observed. Studies in open-chest anesthetized dogs have usually shown that propranolol decreased flow in nonischemic regions and did not change flow in ischemic regions.7-9 In contrast, in closed-chest anesthetized or conscious dogs, propranolol decreased flow in nonischemic regions but flow in ischemic regions increased slightly.10 1 1 Other experimental studies have suggested that all coronary constriction after administration of propranolol is secondary to changes in metabolism and that no direct vasoconstriction from fl-blockade occurs.'2 In patients undergoing cardiac catheterization, propranolol has been shown to induce only slight decreases in global estimates of coronary blood flow and these were totally reversed by restoration of the heart rate to baseline values.'3 14 Clinical benefit was demonstrated by an increase in the pacing-heart rate threshold at angina in most patients in one study13 but not in the other.'4 No prior study has evaluated either clinical or coronary hemodynamic effects of a fixed, fl-blocking dose of intravenous propranolol in patients during acute coronary occlusion. It was impossible to predict changes in coronary collateral flow or resistance after propranolol because of important differences between the coronary circulations of animals and of humans with atherosclerotic heart disease, because of the heterogeneous findings in animal experiments of acute coronary occlusion, and because of the lack of similar experiments in patients.
Our patients represented a relatively homogeneous group, most of whom had single-vessel disease and preserved left ventricular function. No hemodynamic finding in the angiographic or other control or propranolol period separated the 10 patients who benefited from the six who did not. Most patients seemed to derive clinical benefit from propranolol, and in these subjects collateral flow and resistance were unchanged after propranolol, despite a decrease in hemodynamic estimates of global myocardial oxygen demand. The patients who did not clinically benefit had a decrease in collateral flow and an increase in collateral resistance after propranolol. As noted, neither baseline angiographic nor control period coronary hemodynamic indexes of coronary collateral function separated these two groups; however, hemodynamic indexes of collateral function improved only in patients receiving clinical benefit. Thus, the balloon-occlusion preparation allowed some insight into the mechanisms of propranolol's clinical effect.
Our technique for estimating coronary collateral function during balloon occlusion of the left anterior descending coronary artery requires several hemodynamic assumptions: (1) aortic pressure is similar to the pressure at the origin of the collateral vessels, (2) distal coronary pressure measured by the balloon dilation catheter during balloon occlusion of the coronary artery is similar to pressure at the end of the collateral vessels, and (3) great cardiac vein blood flow is an index of residual flow to the anterior left ventricular region. These assumptions seem reasonable when applied to patients who have no important stenoses in adjacent vessels and they have been applied in experiments in animals and in patients undergoing coronary bypass surgery.15"g The use of great cardiac vein blood flow as an index of residual or collateral flow to the anterior left ventricular region should also be reasonable, provided (1) the flow is measured in the distal great cardiac vein near its juncture with the anterior interventricular vein, and (2) the left anterior descending artery is totally occluded before the origin of proximal diagonal or septal branches.2024 These conditions were met in each of our patients. Coronary collateral resistance can be calculated in several ways, but we used a method proposed by Schaper et al. 15 These pressure and flow measurements should be taken only as estimates of coronary collateral function, but they do separate patients with chronic, angiographically visible collateral vessels from those without visible collateral vessels. 4 19 In our experience, repeated brief coronary occlusions led to similar clinical, ECG, and hemodynamic changes as long as duration of occlusion was constant and no medication was administered. Presence or absence of typical angina and of transient ECG changes were used as indicators of myocardial ischemia. To quantitate myocardial ischemia further, we also used the magnitude and type of ECG change, severity of angina, and time to their occurrence. The specificity and sensitivity of these indexes as estimates of the severity of transient myocardial ischemia are debatable, and are hence a possible limitation of this study. Other techniques that might be used to assess or quantitate transient myocardial ischemia in patients undergoing angioplasty include changes in (1) electrograms recorded from the intracoronary wire (2) precordial ECG maps, (3) regional left ventricular wall motion,25 or (4) left ventricular dP/dt. 25 These data have relevance to several clinical situations. First, in patients undergoing coronary angioplasty there is a trend to perform longer balloon inflations in the hope of decreasing the percentage of patients with restenosis of the vessel. Zalewski et al. 6 have reported that propranolol administered directly into a coronary artery allowed longer periods of balloon occlusion before development of myocardial ischemia. Thus, /3-blockade delivered selectively to the affected myocardial region or systemically may decrease the myocardial ischemia that occurs during coronary angioplasty and may allow longer balloon inflations. Second, patients with unstable anginal2 and some with exertional angina26 27 have clinical and ECG evidence of transient myocardial ischemia at rest or during normal daily activity. Transient increases in coronary artery tone or transient coronary thrombosis, or both, can produce reversible periods of coronary occlusion leading to myocardial ischemia. Our data do not address mechanisms leading to, or treatment designed to prevent transient coronary occlusion, but do suggest that the resulting myocardial ischemia may be better tolerated in many patients receiving propranolol. Third, prolonged thrombotic coronary occlusion is believed to be the primary mechanism leading to acute myocardial infarction.3 Benefit from /3-blockade in patients with acute myocardial infarction has previously been demonstrated in several clinical studies.28-31 Recognizing the difficulties in extrapolating data obtained during brief periods of coronary occlusion to more prolonged periods of occlusion and myocardial ischemia, we believe further study of this approach is warranted to assess whether or not it has utility in choosing regimens to be tested in clinical trials of patients with unstable angina or acute myocardial infarction.
In summary, patients undergoing clinically indicated coronary artery angioplasty provide the opportunity to study the effects of acute coronary occlusion in humans and provide new insight into acute myocardial ischemia.
